

CLAIMS

1. An agent for the treatment of hyperglycemia, said agent consisting of cell walls of yeast of the genus *5 Saccharomyces cerevisiae*, said yeast cell walls having:
 - a total glucan and mannan content of at least 34.0% by mass on a dry matter basis, preferably of at least 40.0% by mass on a dry matter basis and preferably still of at least 45.0% by mass on a 10 dry matter basis, and
 - a glycogen content of less than 10.0% by mass on a dry matter basis, preferably of less than 8.0% by mass on a dry matter basis, preferably still of less than 5.0% by mass on a dry matter basis, and more preferably still of less than 3.0% by mass on a dry matter basis.
2. The agent according to claim 1, in which the yeast cell walls have a total glucan and mannan content of less than or equal to 70% by mass on a dry matter basis. 20
3. The agent according to either of claims 1 and 2, in which the yeast cell walls have a total glucan and mannan content of 55% to 70% by mass on a dry matter basis, preferably of 60% to 70% by mass, and preferably still of 60% to 65% by mass on a dry matter basis. 25
4. The agent according to any one of the preceding claims, in which the yeast cell walls have a glycogen content of less than 1.0% by mass on a dry matter basis, preferably of less than 0.1% by mass on a dry matter basis. 30
- 35 5. The agent according to any one of the preceding claims, in which the yeast cell walls have a dry matter content greater than or equal to 90%, preferably greater than or equal to 94% and preferably still

greater than or equal to 96% by mass.

6. An agent for the prevention of hyperglycemia, said agent consisting of yeast cell walls as defined in any 5 one of the preceding claims.

7. The agent according to any one of the preceding claims, characterized in that the hyperglycemia is a hyperglycemia in the case of type 2 diabetes.

10 8. An agent for the stabilization of glycemia, the agent consisting of yeast cell walls as defined in any one of claims 1 to 5.

15 9. The agent according to claim 8, for the stabilization of glycemia in the case of type 2 diabetes.

20 10. A preparation for the treatment of hyperglycemia, preparation comprising yeast cell walls as defined in any one of claims 1 to 5.

25 11. A preparation for the prevention of hyperglycemia, preparation comprising yeast cell walls as defined in any one of claims 1 to 5.

12. Preparation according to either of claims 10 and 11, characterized in that the hyperglycemia is a hyperglycemia in the case of type 2 diabetes.

30 13. A preparation for the stabilization of glycemia, preparation comprising yeast cell walls according to any one of claims 1 to 5.

35 14. The preparation according to claim 13, for the stabilization of glycemia in the case of type 2 diabetes.

15. The use of yeast cell walls according to any one

of claims 1 to 5, in the preparation of a therapeutic composition for the treatment of hyperglycemia.

16. The use of yeast cell walls according to any one
5 of claims 1 to 5, in the preparation of a therapeutic composition for the prevention of hyperglycemia.

17. The use according to either of claims 15 and 16,
characterized in that the hyperglycemia is a
10 hyperglycemia in the case of type 2 diabetes.

18. The use of yeast cell walls according to any one of claims 1 to 5, in the preparation of a therapeutic composition for the stabilization of glycemia.

15

19. The use according to claim 18, for the preparation of a therapeutic composition for the stabilization of glycemia in the case of type 2 diabetes.